Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
May 15 2023 - 8:47AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron-mediated cell death, and immuno-oncology targeted novel
biologics, today announced the appointment of Kelly Anderson to its
Board of Directors and committees, effective as of May 9, 2023.
Mrs. Anderson brings over 25 years of experience
in public company finance, accounting and corporate governance
across a variety of industries and will be instrumental in guiding
Hillstream with its organizational management, business development
and research and development initiatives.
“Kelly has served as a CFO and brings expertise
in partnering negotiations and business development,” said Randy
Milby, Chairman and CEO of Hillstream. “We believe her proven
cross-industry experience and track record of building sustainable
long-term value will further bolster our Board’s depth of expertise
and diversity of thought especially as we further develop our
immuno-oncology targeted biologics portfolio led by anti-HER2 and
anti-HER3 monoclonal antibodies. As such, it is a top priority for
us to have the right team in place to guide us through the
execution of our goals so that we can expand our efforts to develop
and commercialize on our drug candidates.”
“I am excited to be joining the Board of
Hillstream BioPharma and look forward to working alongside the team
as we further our ongoing development programs. I believe the
Company’s precision medicine immuno-oncology strategy with the
current HER2/HER3 antibody developments, has the potential to bring
much needed treatments to cancer patients,” said Mrs. Anderson.
Kelly Anderson currently serves as Chief
Executive Officer of CXO Executive Solutions, a specialized
executive talent solutions company. From 2015 through 2020, she
served as a partner in C Suite Financial Partners, a financial
consulting firm serving private, private equity, entrepreneurial,
family office and government-owned firms across the entertainment,
aerospace/defense, Software-as-a-Service and manufacturing
industries. Mrs. Anderson previously served in senior financial
executive posts at companies including Mavenlink (now known as
Kantata), Ener-Core, Fisker Automotive, T3 Motion and The First
American Corporation. In addition, Mrs. Anderson currently serves
as on the board of AgEagle Aerial Systems Inc., Tomi
Environmental Solutions and Concierge Technologies and was
previously a member of the board of directors of Marygold
Companies, Guardion Health Sciences and Psychic Friends Network.
She is a Certified Public Accountant in California and received her
B.A. in business administration with an accounting concentration
from California State University, Fullerton.
About Hillstream BioPharma,
Inc.Hillstream BioPharma, Inc. is a biotechnology company
developing a focused portfolio of therapeutic candidates targeting
drug resistant and devastating cancers. The Company anticipates
submitting an investigational new drug application and plans to
initiate a clinical study in the second half of 2023 with HSB-1216,
which targets ferroptosis, an emerging new anti-cancer mechanism,
resulting in iron mediated cell death (IMCD) of drug resistant
cancers. The Company’s emerging immuno-oncology pipeline is led by
HSB-3215, a novel anti-HER2 monoclonal antibody targeting unique
epitopes with a novel mechanism of action. The erbB/HER family of
cell surface proteins include well-known and validated drug targets
including HER2 and HER3 found in multiple solid tumors, including
breast, lung, GYN, endocrinological and CNS. For more information,
please visit: www.hillstreambio.com.
Forward Looking
StatementsCertain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
using words such as “anticipate,” “believe,” “forecast,”
“estimated” and “intend” or other similar terms or expressions that
concern Hillstream’s expectations, strategy, plans or intentions.
These forward-looking statements are based on Hillstream’s current
expectations and actual results could differ materially. There are
several factors that could cause actual events to differ materially
from those indicated by such forward-looking statements. These
factors include, but are not limited to, clinical trials involve a
lengthy and expensive process with an uncertain outcome, and
results of earlier studies and trials may not be predictive of
future trial results; our clinical trials may be suspended or
discontinued due to unexpected side effects or other safety risks
that could preclude approval of our product candidates; risks
related to business interruptions which could seriously harm our
financial condition and increase our costs and expenses; dependence
on key personnel; substantial competition; uncertainties of patent
protection and litigation; dependence upon third parties; and risks
related to failure to obtain Food and Drug Administration (“FDA”)
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2022 and our periodic reports filed
with the Securities and Exchange Commission. However, these risks
are not exhaustive and new risks and uncertainties emerge from
time to time and it is not possible for us to predict all risks and
uncertainties that could have an impact on the forward-looking
statements contained in this press release. Forward-looking
statements included herein are made as of the date hereof, and
Hillstream does not undertake any obligation to update publicly
such statements to reflect subsequent events or circumstances,
except as may be required by law.
Investor Relations
ContactEmail: investorrelations@hillstreambio.com www.hillstreambio.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/6299b599-a1e7-472b-896b-fc8b160fcce0
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2023 to Apr 2024